Semaglutide is marketed under the brand names ... which is commonly prescribed for weight loss. The drug mimics the GLP-1 hormone in your body which helps regulate insulin and reduces and controls ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Data from a large, randomized clinical trial named SELECT indicate cardiovascular protective benefits from taking the GLP-1 weight loss therapeutic Wegovy (semaglutide) for a sub-population with ...

A low bioavailability indicates less of the semaglutide will be properly absorbed by the body. Evidence in recent years showing GLP-1’s potential link in treating neurodegenerative disease ...